Mesenchymal Stem Cells

Homogenous populations of perivascular-like MSCs might exhibit more robust responses to inflammatory insult and provide a more “powerful” therapeutic approach

Osteocyte‐derived mechanically-activated extracellular vesicles hold great potential as a novel cell‐free therapy to enhance bone regeneration

MSC chondrogenesis represents a transient property lost as cells age in vitro, whereas trophic repair potency is maintained until MSCs cease to grow. 

A new review article in STEM CELLS discusses the underrated role of alternative splicing, a process that produces multiple similar but functionally distinct proteins from one gene, in MSC differentiation

Mesenchymal stem cell (MSC) therapy represents a promising option for the treatment of steroid‐refractory chronic graft‐vs‐host disease (cGvHD); however, we lack clinical trial data, and the mechanisms of action remain unknown.

A concise review article published recently in STEM CELLS Translational Medicine from Marcin Majka and Bogna Badyra (Jagiellonian University Medical College, Cracow, Poland)

New research shows how MSC-secreted factors can impair biofilm formation by cutaneous wound‐related bacteria and disrupt mature biofilms via a protease‐dependent mechanism

The unique properties of mesenchymal stem cells (MSCs) have made them an exciting resource for the treatment of a range of human conditions, including degenerative and inflammatory diseases, tissue damage, and cancer.

Although the systemic administration of mesenchymal stem cells (MSCs) ameliorates lung inflammation and attenuates fibrosis in experimental silicosis, MSC therapy fails to reverse collagen deposition and granuloma formation.

Stimulation via the canonical Notch ligand, Jagged1, or bone morphogenetic proteins (BMP) can induce the osteoblastic differentiation of bone-marrow-derived human mesenchymal stem cells (hMSC); however, the question as to how these two pathways lead to the same phenotypic outcome remains unanswered.